I googled ldg-4033. Everything seems consistant to dylans data. Here is some data from the interweb. Sorry for the semi hijack dylan.
Selective Androgen Receptor Modulator (SARM
is a non-steroidal selective androgen receptor modulator (SARM
), expected to produce the therapeutic benefits of testosterone
with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Ligand has discovered several novel orally active, non-steroidal SARM
compounds, including LGD-4033
, based on tissue-specific gene expression and other functional, cell-based technologies. In animal models, LGD-4033
demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033
has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers.
Goals of SARM
Improve Lean Body Mass (LBM) Improve muscle strength Improve Physical Performance
Enhance Quality of Life(QOL) LGD-4033
has the potential to prevent and treat a variety of muscle wasting conditions:
Phase I single and multiple dose escalation studies of LGD-4033
were conducted in a total of 116 healthy male subjects. The safety, tolerability and preliminary efficacy of LGD-4033
was evaluated in the double-blind, placebo-controlled Phase I multiple ascending dose study. Healthy male subjects were randomized to receive 0.1, 0.3 or 1.0 mg LGD-4033
or placebo once daily over 21 days.
Key findings of this study include: LGD-4033
was safe and well tolerated at all doses following daily oral administration for three weeks in young healthy males No clinically significant dose-related adverse events were reported No clinically significant changes in liver function tests, PSA, hematocrit or ECG were seen Positive dose-dependent trends in lean muscle mass increase were observed with drug-treated subjects Positive dose-dependent trends in functional exercise and strength measures were consistent with anabolic activity LGD-4033
is positioned to enter into Phase II development. Studies are planned to evaluate LGD-4033
over 12-weeks of oral dosing in conditions such as muscle wasting associated with cancer, acute rehabilitation (e.g. hip fracture), and acute illness. Cachexia is a wasting syndrome defined by progressive weight loss, anorexia, and muscle atrophy. Cachexia is a significant factor in the poor Performance
status and high mortality rate of patients in multiple disease states such as cancer, COPD, severe burns, AIDS and end stage renal disease. Cachexia significantly impairs quality of life and response to medical treatment. Approximately 25% of all cancer deaths can be attributed to cachexia.